By Product Type
By Research Area
Dr. Samaresh Sau, research associate at Wayne State University, discusses novel personalized therapies using dexamethasone and click chemistry based nanotherapy.
There are innumerable cancer drugs with solid mechanisms of action that fail in clinical trials, costing significant time, money, and effort. Is it possible to repurpose and save these drugs? Dr. Sau presents evidence that, in some cases, optimization through chemistry and combination therapy can change the fate of drugs. For example, dexamethosone itself affects healthy and cancer cells. However, a few chemical modifications can make it more potent towards cancer cell and have fewer side effects on healthy cells. In another case, jak-stat3 kinase inhibitor WP1066 failed to progress beyond phase I trials, but when used with a dexamethasone derivative, it is more efficacious and can be used at a lower dose. To learn more about this and how click-chemistry nanotherapy can be used to target cancer cells, watch this webinar.
1. Cationic lipid-modified dexamethasone derivative is a potent cancer drug and does not affect non-cancer cells.
2. WP1066 and dexamethasone derivative synergize to kill tumors.
3. Click-chemistry can be used to add personalized 'tumor-honing' molecules to therapeutic nanoparticles to increase efficacy and minimize toxicity.
Showcase your research to the world!
- Your webinar will have a permanent residence on the Proteintech website.
- Use the Proteintech website, email newsletter and social media as your platform.
- Access to materials to record your 15-min presentation included.